In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.